Curis (CRIS)
(Delayed Data from NSDQ)
$16.36 USD
-0.15 (-0.91%)
Updated May 3, 2024 04:00 PM ET
After-Market: $16.67 +0.31 (1.89%) 5:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Curis, Inc. [CRIS]
Reports for Purchase
Showing records 61 - 80 ( 302 total )
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Promising Erivedge Numbers; Looking Forward to ''907 data
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Aurigene Collaboration Marks Entry Into Immuno-oncology Space
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
''907 Expands Into Solid Tumors With First Dosed Patient
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Results; ''907 Shows Promising Signs in DLBCL
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Additional IP Protection in Place as ''907 Program Ramps Up; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
3Q14 Erivedge Sales Flat, but Roche Committed to Expansion; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Healthcare - Potential Short-term Weakness in AML, but Approaches Are Differentiated
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
CUDC-907 Program Advances; Picking Up The Clinical Pace
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
2Q14; Road Getting CRIStal Clear For Erivedge Growth & Pipeline Progress
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Erivedge Building on its Strong Traction and Growth; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Curis, Inc.
Industry: Medical - Biomedical and Genetics
Erivedge Expands into Non-Oncology Indications; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J